In this week's video, Dr. Brian G.M. Durie discusses what patients and caregivers need to know about the recent approval of elotuzumab (Empliciti).

Bottom Line:

Empliciti is a useful drug when used in combination with Rev/dex in a relapse setting.

Dr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.